US FDA Advisory Committee Conduct Could Take Center Stage in Lykos Appeal of MDMA Rejection

 
• By Sarah Karlin-Smith
  
Generate a summary of this article
Listen to this article
Beta

Sponsor of psychedelic PTSD treatment will try rarely successful formal dispute resolution process after receiving a complete response letter. 

image of large meeting taking place with people around a table and charts of information being displayed.
The advisory committee's focus on information not in the NDA or briefing book will be part of Lykos' CRL appeal. • Source: Shutterstock

Lykos reiterated its concerns about the “structure and conduct” of the June advisory committee meeting for its MDMA therapy for post-traumatic stress disorder as it prepares to formally challenge the US Food and Drug Administration’s 9 August complete response letter.

Key Takeaways

  • Lykos plans to use the Psychopharmacologic Drugs Advisory Committee’s conduct and the FDA’s ongoing advisory committee reform to justify reconsideration of its complete response letter.

The sponsor of midomafetamine assisted therapy (MDMA-AT) plans to request a meeting with the FDA to ask for reconsideration of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

US FDA Advisory Committee Conduct Could Take Center Stage in Lykos Appeal of MDMA Rejection

 
• By Sarah Karlin-Smith

Sponsor of psychedelic PTSD treatment will try rarely successful formal dispute resolution process after receiving a complete response letter. 

Steady On For US FDA’s Novel Approvals At Mid-Year, But Another 2023 Is Unlikely

 
• By Bridget Silverman

US FDA would need to approve 44 novel agents by year-end to match 2023’s big total, but only 40 candidates are known to have user fee goals in the second half of 2024.

Pharma Looks To America First: US FDA Holds Overwhelming Lead Over EMA In Novel Approvals

 
• By Bridget Silverman

A Pink Sheet analysis finds US approval preceded European Union clearance for 80% of products approved in both areas, but when EU approval came first, it beat the FDA by a median of 13 months. US-first approvals came close to six months before the EU.

More from Product Reviews

data

New EU Filings

 
• By Saba Afreen

<p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

data

EU CHMP Opinions And MAA Updates

 
• By Saba Afreen

<p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>